Concentra Group (CON) Fair Value & Analysis
Healthcare · US · Market cap $3.2B
Concentra Group
CON · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from $26.86 to $28.42 (+5.8%) since Jun 23, 2026. Share price +19.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $17.86 – $29.05 · fair‑value band $10.98 – $37.14 · the $28.66 price screens above the $28.42 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Concentra Group (CON) currently trades at $28.66, while our model-based Fair Value estimate is $28.42 — implying the stock looks roughly 0.8% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Concentra Group generated revenue of $2.2B at a net margin of 8.0%. Revenue grew 13.7% year over year. It earns a return on equity of 47.0%. Net debt stands at $2.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing,…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Concentra Group reported revenue of $2.2B in FY2025 versus $1.7B in FY2021, a compound +5.7%/yr. Reported net income was $173M in FY2025, compounding −4.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Concentra Group (CON) undervalued?
What is the fair value of CON?
What is the quality score of CON?
What is the revenue of Concentra Group (CON)?
What is the net profit margin of CON?
Does Concentra Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.